Graft Polymer Refocuses on Mental Health Biotech
Company Announcements

Graft Polymer Refocuses on Mental Health Biotech

Graft Polymer (UK) PLC (GB:GPL) has released an update.

Graft Polymer (UK) PLC, a biotech firm specializing in mental health treatment development, has strategically refocused its business by appointing a new CEO, Anthony Tennyson, and shifting towards healthcare, particularly in treating mental health and substance use disorders. The company has streamlined its operations by divesting its industrial polymer division and raising £1.8 million for growth. They’ve also initiated a collaboration with Awakn Life Sciences Corp. to co-develop therapeutics for trauma-related disorders like PTSD, and are strengthening their IP portfolio with new patent applications.

For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskGraft Polymer Advances PTSD Therapeutic Research
TipRanks UK Auto-Generated NewsdeskGraft Polymer Advances PTSD Treatment Research
TipRanks UK Auto-Generated NewsdeskGraft Polymer Welcomes New Chairman
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App